Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Enfuvirtide Fuzeon
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Abacavir Ziagen
Abacavir-Lamivudine Epzicom
Abacavir-Lamivudine-Zidovudine Trizivir
Didanosine Videx
Emtricitabine Emtriva
Lamivudine Epivir
Stavudine Zerit
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF Viread
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Zidovudine Retrovir
Zidovudine-Lamivudine Combivir
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Nevirapine Viramune
Rilpivirine Edurant
Atazanavir Reyataz
Atazanavir-Cobicistat Evotaz
Darunavir Prezista
Darunavir-Cobicistat Prezcobix
Fosamprenavir Lexiva
Indinavir Crixivan
Lopinavir-Ritonavir Kaletra
Nelfinavir Viracept
Saquinavir Invirase
Tipranavir Aptivus
Cobicistat Tybost
Ritonavir NorvirSelf-StudyPrevention of HIV
Apply Evidence-Based Recommendations for the Prevention of HIV Transmission
Sign In or Register to get started
Apply Evidence-Based Recommendations for the Prevention of HIV Transmission
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 5 Overview
HIV Preexposure Prophylaxis (PrEP) - 0%Topic 1
IntroductionActivities- 0%Topic 2
Persons to Consider for HIV PrEPActivities- 0%Topic 3
Recommended Regimens and Dosing for HIV PrEPActivities- 0%Topic 4
Baseline Laboratory Evaluation, Immunizations, and CounselingActivities- 0%Topic 5
Major HIV PrEP StudiesActivities- 0%Topic 6
Time to Achieve Protection after Initiating HIV PrEPActivities- 0%Topic 7
Impact of Adherence on Efficacy of HIV PrEPActivities- 0%Topic 8
Laboratory Monitoring on HIV PrEPActivities- 0%Topic 9
Acquisition of HIV in the Setting of HIV PrEPActivities- 0%Topic 10
HIV PrEP and Development of HIV Drug ResistanceActivities- 0%Topic 11
Adverse Effects of Medications Used for HIV PrEPActivities- 0%Topic 12
Changes in Sexual Practices Among Persons Receiving HIV PrEPActivities- 0%Topic 13
Discontinuing PrEPActivities- 0%Topic 14
Transitioning from Nonoccupational HIV PEP to HIV PrEPActivities- 0%Topic 15
Disparities in HIV PrEP UseActivities- 0%Topic 16
Future HIV PrEP MedicationsHIV Preexposure Prophylaxis (PrEP) Overview
About this Lesson
Last Updated: December 22nd, 2023CNE/CME Continuing Education
This lesson qualifies for:- 2 CME AMA PRA Category 1 Credits™, or
- 2 CNE contact hours and 2 CE contact hours (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: July 1st, 2017CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
1Quiz
Score 80%+2Give Feedback
Complete survey3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled HIV Preexposure Prophylaxis (PrEP) and available until September 1st, 2023.Learning Objectives
- List persons to consider who may benefit from HIV PrEP
- Explain recommendations for testing and counseling prior to starting PrEP
- Discuss the recommended PrEP regimens, including dosing, safety, efficacy, and clinical eligibility
- Describe recommended clinical and laboratory baseline evaluation and monitoring for persons receiving HIV PrEP
- Summarize initial management of persons who develop HIV while receiving HIV PrEP
Lesson Contributors
Authors
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneAley G. Kalapila, MD, PhDAley G. Kalapila, MD, PhD
Associate Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health SystemDisclosures:NoneReviewers
Brian R. Wood, MDBrian R. Wood, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE provided byUniversity of Washington School of NursingCopyright © 2024 National HIV CurriculumThe National HIV Curriculum is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,172,990 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.govSince you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-a3460488-2024-11-13-205621 - 0%Topic 2